Spirocycle integrin inhibitors

Details Spirocycle integrin inhibitors Spirocycle integrin inhibitors

C - Chemistry, Metallurgy

07

D

C07D 413/12 (2006.01) A61K 31/41 (2006.01) A61K 31/435 (2006.01) A61K 31/495 (2006.01) A61K 31/53 (2006.01) A61K 31/535 (2006.01) A61K 31/54 (2006.01) A61K 31/675 (2006.01) C07D 261/20 (2006.01) C07D 401/12 (2006.01) C07D 401/14 (2006.01) C07D 405/14 (2006.01) C07D 409/14 (2006.01) C07D 413/14 (2006.01) C07D 417/14 (2006.01) C07D 453/02 (2006.01) C07D 471/04 (2006.01) C07D 473/00 (2006.01) C07D 475/00 (2006.01) C07D 487/10 (2006.01) C07D 498/04 (2006.01) C07D 498/10 (2006.01) C07D 513/04 (2006.01) C07D 513/

Patent

CA 2249733

This invention relates to novel heterocycles, including (S)-2- phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]- dec-2-en-3-yl]carbonylamino]propionic acid, which are useful as antagonists of the .alpha.v.beta.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Cette invention concerne de nouveaux hétérocycles, comprenant l'acide (S)-2-phénylsulfonylamino-3[8-(2-pirydinilaminométhyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionique, qui sont utiles en tant qu'antagonistes de l'intégrine .alpha.¿v?.beta.¿3? et les récepteurs apparentés de protéines adhérant à la surface de cellules, l'invention concernant également des compositions pharmaceutiques contenant ces composés, des procédés de préparation de ces composés, ainsi que des méthodes d'utilisation de ces composés, seuls ou combinés à d'autres agents thérapeutiques pour empêcher l'adhésion cellulaire, le traitement de troubles angiogéniques, l'inflammation, la dégradation osseuse, les métastases de cancer, la rétinopathie diabétique, la thrombose, la resténose, la dégénération maculaire et d'autres états pathologiques induits par l'adhésion cellulaire et/ou la migration cellulaire et/ou l'angiogenèse.

Affiliated with

Also associated with

Rating

Spirocycle integrin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spirocycle integrin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirocycle integrin inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1440568